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Abstract 
Mobile Health (mHealth) uses mobile communication devices such as smartphones and tablet 
computers to support and improve health-related services, data flow and information, patient self-
management, surveillance, and disease management from the moment of first diagnosis to an 
optimized treatment. The European Academy of Allergy and Clinical Immunology created a task 
force to assess the state of the art and future potential of mHealth in allergology. The task force 
endorsed the “Be He@lthy, Be Mobile” WHO initiative and debated the quality, usability, efficiency, 
advantages, limitations, and risks of mobile solutions for allergic diseases. The results are 
summarized in this position paper, analyzing also the regulatory background with regard to the 
“General Data Protection Regulation” and Medical Directives of the European Community. The task 
force assessed the design, user engagement, content, potential of inducing behavioral change, 
credibility/accountability, and privacy policies of mHealth products. The perspectives of health care 
professionals and allergic patients are discussed, underlining the need of thorough investigation for 
an effective design of mHealth technologies as auxiliary tools to improve quality of care. Within the 
context of precision medicine, these could facilitate the change in perspective from clinician- to 
patient-centered care. The current and future potential of mHealth is then examined for specific 
areas of allergology, including allergic rhinitis, aerobiology, allergen immunotherapy, asthma, 
dermatological diseases, food allergies, anaphylaxis, insect venom, and drug allergy. The impact of 
mobile technologies and associated big data sets are outlined. Facts, recommendations, and an 
action plan for future mHealth initiatives within EAACI are listed. 
 
1. Becoming Wireless – The Frantic Evolution of Information and Communication 
Technologies   
Today´s world is connected wirelessly. This is reflected by the fact that the amount of mobile phone 
subscriptions has overtaken the number of people on the planet, a phenomenon being accompanied 
by a growing number of broadband connections for these phones, which creates a ubiquitous 
mobile infrastructure [1]. This chance has been seized by a multitude of companies, developers, 
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private entrepreneurs and start-ups, which has created an avalanche of mobile applications (Apps) 
with services mainly focused on entertainment, infotainment and the ease of daily life procedures. 
Interestingly, the development of healthcare related Apps and devices represents the fastest 
growing area within the information and communication technology (ICT) sector. This offers 
immense opportunities for global healthcare systems facing the challenge of improving patient care 
by making it more precise, efficient and cost-effective while improving accessibility especially for 
remote areas.  To date, most of the evolution in the Mobile Health (mHealth) sector has been driven 
by private companies but central structures to ensure the quality of existing and new products have 
not yet been established. This urgent need has been recognized by the World Health Organization 
(WHO) [2], the European Union, national governments and a multitude of medical associations [3].  
 
As millions of patients suffering from allergic diseases may benefit from mHealth innovations, the 
European Academy of Allergy and Clinical Immunology (EAACI) created a task force to assess the 
state of the art as well as the future potential of ICT in the field of allergy.  The evaluation of 136 
mobile applications in 2016 depicted a broad heterogeneity in terms of content and quality. As the 
mobile health environment is a very dynamic field, some of these may no longer exist or comply with 
regulatory requirements. Very few apps had been clinically validated and many were not based on 
guidelines or clinical evidence. Since then, various studies have evaluated the advantages, usability, 
efficiency and risks of mobile health technologies in allergic rhinitis [4-6], asthma [7-9], atopic 
dermatitis [10], food allergy [11, 12] and anaphylaxis [13].  
 
Recognizing this scenario, the EAACI Task Force has created a position paper, summarizing general 
aspects such as legal regulations and evaluation criteria before evaluating the role of mHealth 
technologies in the respective allergic diseases. Finally, a roadmap for future actions of EAACI for the 
improvement of patient care through mHealth strategies will be depicted, considering possible 
limitations. A selected list of allergy-related Apps will be given in the appendices. 
 
2. Endorsement of mHealth policy by WHO and American College of Allergy, 
Asthma and Immunology 
2.1. “Be He@lthy, Be Mobile” – a WHO Initiative  
The “Be He@lthy, Be Mobile” (BHBM) initiative is a global partnership led by the World Health 
Organization (WHO) and the International Telecommunication Unit (ITU) [14]. It supports scale up of 
mHealth within national health systems to help combat diabetes, cancers, cardiovascular and 
chronic respiratory diseases. As mobile technologies and internet access are also widely spread  in 
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countries with low average incomes, WHO recognized mobile health technologies as a valuable tool 
in providing healthcare to populations in remote areas or with limited access to health 
infrastructure. Training and self-empowerment become especially important in these cases. The 
handbook “mBreatheFreely” refers to the use of mobile technology to provide health information 
and support for people living with asthma and COPD. It provides guidance for governments and 
policymakers to develop, implement, and evaluate an mBreatheFreely program for the prevention 
and control of both diseases. The health messaging provided uses evidence-based behavior change 
techniques to help persons at risk of or affected by asthma and COPD to prevent and manage these 
conditions.  
 
In addition to guidance for the implementation of concrete programs, WHO also initiated an 
mHealth Technical Evidence Review Group. Together with a panel of external experts, this group 
created a check-list of 16 items to standardize and improve the quality of mHealth evidence 
reporting [15].  
 
2.2. Telemedicine in Allergy (Position Paper of the American College of Allergy, Asthma & 
Immunology)  
The American College of Allergy, Asthma and Immunology (ACAAI) created a task force to evaluate 
the advantages and limitations of digital technologies within the broader scope of telemedicine [3]. 
In summary, ACAAI considers telemedicine a valuable method for health care delivery, especially to 
patients in rural or remote areas. The paper states that it may enhance patient-doctor collaborations 
and improve adherence as well as health outcomes. By facilitating access to specialists, it is valuable 
especially for allergic patients whose condition often requires prompt assessment, a need often 
hindered by long waiting lists for appointments with specialists. Although underlining the strength 
and positive potential of eHealth, the authors mention various challenges, such as standardized 
regulations, privacy, security, licensing, credentialing and reimbursement. This position paper gives a 
valuable general background for the evaluation of mHealth services in allergy care. 
 
3. Regulatory Background 
3.1. Legal Background for Centralized Quality Control and Risk Management  
To access markets, minimize risks and gain relevance by providing the necessary level of trust, 
mHealth services must meet requirements of numerous legal domains. Unfortunately, many of 
these  
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lack international harmonization. For instance, medical liability and remote treatment are not 
covered by multi-national treaties or acts and differ across Europe. Thus, an international standard 
covering all legal aspects of m-Health in detail is not achievable. However, certain legal areas offer 
instruments for creating multi-national standards. For example, the “General Data Protection 
Regulation” [16] incentivizes the development of domain-specific Codes of Conduct by providing 
proof of compliance within the whole of Europe; an example addressing mHealth can be found 
online [17]. Any standardization initiative should use such tools extensively. To reflect the 
importance of full compliance in non-harmonized legal domains, those initiatives should additionally 
identify and implement equal international requirements as far as possible - supplemented by the 
obligation of a full legal compliance assessment for each territory in which a service is provided. In 
addition, technologies incorporating medical diagnosis and intervention should be registered as a 
medical device (Medical Device Directive 43/42/EWG) and obtain CE certification (CE1, CE2). 
Regulations and their interpretations are evolving and as such, any recommendations will need to be 
regularly updated.  
 
3.2 Evaluation Criteria for mHealth Tools  
Any medical intervention or tool, including mHealth Apps, may have potential risks and benefits [18] 
Several tools to assess Health App quality have been developed. The first methods covered mainly 
usability [19] while others focused on the development and life cycle of the App [20]. The Health 
Care Information and Management Systems Society published a guideline to evaluate the usability, 
but did not include any information quality criteria [21]. Newer tools have been developed, 
informed by systematic reviews of the literature and validated for internal consistency and interrater 
reliability, such as MARS [22], U-MARS (an end-user version)[23] and Enlight [24].  MARS and U-
MARS evaluate engagement, functionality, aesthetics, information (including credibility) and 
subjective quality. Enlight also incorporates domains to assess therapeutic potential and tool 
generalizability. A recent systematic review identified relevant quality domains of user-facing e-
Health programs such as usability, visual design, user engagement, content, behavior 
change/persuasive design, influence of social presence, therapeutic alliance, classification, 
credibility/accountability, and privacy/security, and highlights a high degree of agreement on these 
criteria around the globe [25]. Several institutions are beginning to offer mHealth accreditation.   
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4. Stakeholders´ Role  
4.1. The use of mHealth technologies from the patients´ perspective 
Patients may use mHealth for multiple reasons, which may not be aligned with the aims and 
objectives of clinicians [26] “Patient centred care should be personalised, pro-active and patient 
driven” [27]. Health care needs and wants have to be differentiated. App design should incorporate 
facultative use to enable tailoring [28]. To ensure patient centeredness and relevance, patients 
should be involved at every phase of the design, implementation and updating process [15]. For 
patient management, apps could be offered as part of information giving, monitoring and self-
management to facilitate patient participation. Patients need to have confidence in the validity of 
any app used, thus the provenance should be explicit [29,30].   
 
4.2. The use of mHealth technologies from the healthcare professionals´ (HCP) perspective 
HCPs are co-end users of mHealth, and only then, with patient assent. The mismatch of priorities 
between patients and clinicians need to be reconciled prior to developing any mHealth intervention 
to create a therapeutic partnership between patient, clinician and mHealth [15]. Secondary concerns 
of HCPs include incorporating data into electronic health care records and clinical responsibility for 
their use [18].  HCPs attitudes and systems (IT, organizational and incentivisation) will need 
significant reorientation to incorporate mHealth into routine medical care, which will require 
permissive cultural and organizational changes [31,32].  
 
 mHealth is an integral part of clinical care as an auxiliary feature aimed at improving quality of care, 
patient outcomes, and delivering efficiencies. The immediacy of app interaction and how this is 
provided (algorithmically or personally) needs to be addressed. Research is needed to understand 
the patterns of patient usage of Apps as well as the impact of mHealth technologies that require a 
prescription or formal physician oversight (digital therapeutics).  Within the context of personalized 
precision medicine, mHealth Apps could facilitate the change of the model of care from clinician- to 
patient-centered care [33].  
 
5. mHealth in Allergic Diseases 
5.1. Allergic Rhinitis  
 
Currently, the impact of mHealth on the diagnosis of rhinitis is small, with a limited number of 
mHealth tools for allergic rhinitis (AR) diagnosis published in peer-reviewed journals [34-36, 5]. 
Several others, from which published data is pending, are available on the market. Recent advances 
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in integrated biosensors, wireless communication and power harvesting techniques are spawning a 
new breed of point-of-care devices. However, AR is a very common disease and any diagnostic 
device connectable to a smartphone (e.g. peak nasal inspiratory flow meters, intranasal biosensors) 
will need to be very cheap to be affordable.  
 
The monitoring of the control of allergic multimorbidities (rhinitis, conjunctivitis and asthma) has in 
contrast been approached by several apps. Allergymonitor, for example, allows the monitoring of 
symptoms and medication intake, which is then matched to local pollen concentrations [36, 37, 5]. 
The MASK (Mobile Airways Sentinel Network) MASK-Air, initially called Allergy Diary uses a visual 
analogue scale (VAS) for nose, eye and asthma symptoms, work impairment and a global assessment 
[38]. The data collected by the users of this app has led to new insights on work productivity, 
treatment patterns or phenotypes of allergic diseases.  
 
Another promising aim for mHealth tools is improving our understanding of how patients adhere to 
medication adaptively. Lack of understanding of medication usage is common in all chronic diseases. 
Studies of patients using the MASK App show that users´ behavior is often not in accord with 
guidelines, but patient frequently treat themselves as needed, which results in only less than 5% 
taking medication according to guideline recommendations [39]. These results prompted ARIA to 
develop a self-management strategy rather than targeting an increase of adherence. Nevertheless, 
internet-based telemonitoring improves the taking of intranasal corticosteroid (INCS) and improves 
disease knowledge among children and adolescents with seasonal allergic rhinoconjunctivitis [6]. 
Push notifications offer a promising strategy for enhancing engagement with smartphone-based 
health interventions in allergic rhinitis. 
 
Mobile Apps also have the potential of discovering new allergic disease patterns through the 
acquisition of large data sets. For example, MASK unearthed novel patterns of allergic 
multimorbidity, which had not been demonstrated in a previous study (Mechanisms of the 
Development of Allergy MeDALL) [40]. When applying this new information, novel patterns (asthma, 
rhinitis and conjunctivitis) could then be confirmed on re-analysis of MeDALL data [41].  
 
5.2. Pollen, Fungal Spores and Aerobiology  
People affected by pollen allergy need accurate pollen information/forecasts to assist allergy 
diagnosis, allergen avoidance and symptom management, thus improving quality of life [42,43]. 
Monitoring and forecasting should not be limited to pollen or spore concentrations, but also include 
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other environmental information such as ozone levels, sulfides, nitrogen dioxide, particulate matter 
and others, as these agents, in addition to their non-specific effects, may enhance pollen 
allergenicity [44].  
 
The assessment of pollen and spore levels may aid the identification of clinically relevant allergies to 
specific plants or fungi as well as guiding decisions concerning allergen immunotherapy [36]. 
 
Nowadays, allergic symptoms may be documented electronically in pollen diaries (e.g. [34, 5]). The 
advantages of such online diaries are comprised of continuous monitoring of allergic symptoms, 
enabling comparisons of different years/seasons and with different aerobiological particles, among 
them pollen and fungal spore concentrations. Users learn more about their symptomatic pattern, 
track down a possible pollen allergy (when compared with pollen concentrations) and thus may be 
willing to visit an allergist/medical doctor earlier asking for advice, diagnosis and treatment. In the 
future, the combination of tracking symptoms and evaluating the personal exposure 
(outdoor/indoor exposure) will play a role. 
 
However, certain quality criteria (e.g. the inclusion of pollen data elaborated by institutions capable 
of monitoring/assessing and evaluating aerobiological data bearing the scientific and ethical 
responsibility) should be defined especially concerning accurate pollen and pollutant forecasts and 
their incorporation into mHealth for pollen allergy sufferers to maximise benefits [45].  
 
5.3. Allergen Immunotherapy  
mHealth technology, including telemonitoring, integrated care pathways (ICPs) and clinical decision 
support systems (CDSS) are suggested as potential tools to aid decision-making for AIT, as well as the 
identification of clinical responders to treatment [46-48]. If algorithms are based on evidence-based 
clinical recommendations for AIT such as outlined in the EAACI guidelines [49-51], this technology 
has the potential to optimize the precision for prescriptions [36], as well as efficacious and evidence-
based products in AIT.  When AIT is initiated, mHealth technology may in addition effectively 
increase patients’ adherence [52], which is reported to be low in AIT [53, 54]. Patient support 
programs (PSPs) have suggested improving adherence by integrating and optimizing communication, 
educational, motivational and behavioral modification components [55, 56]. These could be 
implemented in mHealth technology, for example electronic reminder systems, e-communication 
channels, the use of „push“- messaging, gaming, including social networks with caregivers and peers 
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[55]. mHealth telemonitoring is a promising tool to monitor clinical benefits and side-effects of AIT 
including improvement of symptoms and quality of life or medication reduction. These technologies 
are already in use, e.g. as e-diaries in clinical trials of AIT aiming to collect clinical data in real-time 
for research and AIT product development [57]. In addition, real-life monitoring of large populations 
of patients receiving AIT in routine clinical practice both during treatment and after treatment 
cessation (’carry over’-effect) may become possible with mHealth technologies. Additionally such 
large data sets offer the potential of identifying unmet needs to be investigated in the future [47]. 
These may include prospective evaluation of adherence in a real-life population and long-term 
clinical effects after cessation of AIT (which is not feasible in randomized controlled trials for ethical 
reasons, costs and patients’ willingness) or pharmacoeconomic evaluations. The latter is of great 
importance for payors and health-systems. 
 
5.4. Asthma  
mHealth provides not only tools to support patients with asthma in self-monitoring and decision-
making, but also offers a variety of digital therapeutics to support disease management [58,59]. In 
fact, mHealth has the potential to enhance the quality of care, improve adherence to therapy and 
detect deterioration of symptoms by continuous monitoring and feedback to patients. A meta-
analysis demonstrated improved asthma control with the use of mHealth, though the quality of Apps 
was substantially heterogeneous [28]. 
 
Many asthma Apps have been developed and are available for use [60], mainly by adults, but some 
also for school-age children and adolescents [7, 61-64]. Registering the use of a reliever inhaler has 
been used to monitor pediatric asthma control and to provide feedback through an electronic 
treatment plan [7].   
 
The importance of users´ feedback has been underlined by the outcome of a project including 
adolescent volunteers (13-18 years-old) who evaluated two asthma apps (AsthmaMD and Asthma 
Pulse) [62]. The suggested improvements included push-reminders (to take medication and to 
purchase refill), asthma-related games, fun-factors and a built-in flow meter [63]. Recording clinical 
and functional endpoints (i.e. symptoms, FEV1, PEF) on a daily basis, together with allergen and 
pollutant exposure, facilitates continuous asthma monitoring. Smartphone-based technologies for 
the assessment of objective parameters, such as lung function or lung sounds, have been developed 
and are currently being evaluated. Receiving mHealth data prospectively in addition to history taking 
may improve diagnostic precision. mHealth can support tailored asthma patient education, provide 
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reminders and improve self-management (e.g. trigger avoidance, use of rescue therapy and 
behavioral guidance during exacerbations).  Existing randomized-controlled trials (RCT) have mainly 
focused on comparing the effect of Apps on asthma control to paper-based asthma management 
[64, 65].  
 
However, there is lack of long-term RCTs of mHealth for the improvement of asthma control [66].  
With regard to this, hopefully, results from the recently completed multicenter Horizon 2020 EU-
funded project “My Air Coach”, aimed at developing an innovative asthma monitoring system, will 
be able to answer current unmet needs in the field [9]. 
 
5.5. Dermatological Diseases  
Mobile Health can play a role in the care for patients with dermatological allergic diseases, such as 
atopic dermatitis, contact dermatitis, chronic urticaria and cutaneous manifestations of drug 
hypersensitivity. Once the diagnosis has been confirmed, Apps can be useful for the monitoring of 
complaints and other symptoms, the support of patient self-management, the facilitation of 
professional-patient communication, telemedicine and peer support or research. 
 
 The severity and extent of disease can be measured over time for better self-control of the disease 
in form of a patient diary. Using validated questionnaires, which are available in Apps, a graphical 
display of scores over time is shown and patients or caregivers get insight into the course of the 
disease and the effect of the use of medication or topical therapy. There are several validated 
instruments for scoring severity of dermatological diseases [67, 68], and the Patient Oriented Score 
of Atopic Dermatitis (PO-Scorad) has been deployed for use in a mobile App [69] as well as the 
Atopic Dermatitis Activity Score and the Patient Oriented Eczema Measure of the University of 
Nottingham [70]. Other specific tools measure the impact of chronic skin diseases on sleep quality, 
using wearable sleep and/or itch tracker. Medication reminders or adherence apps remind patients 
to use their medication in time and might help to support action plans [71]. 
 
Apps including information about the disease, playful information for children, treatment, living with 
the disease, videos and patient stories can support self-management of patients. Patient portal 
Apps, which allow patients to view their medical file, send e-consultations and request e-repeat 
prescriptions may facilitate patient-doctor communications [72-74]. This may also be supported by 
Apps to share photos between the patient and HCPs as well as between doctors for 
teledermatology. Automated image recognition may deliver additional support for professionals. 
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mHealth can also gather data for research purposes and support communication within patient 
groups.  
 
Skin test results can be assessed and recorded on the skin and in clearly positive or negative 
outcomes could also be evaluated by morphometric analysis, documented, followed-up and shared 
by apps. Computer- or mobile-based morphometric analysis is easier regarding the erythema as 
compared to the wheal associated with positive skin test reactions, because colour changes 
(erythema, blanching due to compression of vessels in the wheal, reflections by vesicles/blisters in 
the patch test) are easier to detect than the swelling of the wheal. Digital photodocumentation of 
skin prick test, patch test and intradermal test results could be collected and analysed by mHealth. 
The principal correlation between doctor-based and computer-based morphometric evaluations of 
positive skin test responses has been reported [75]; however, no program or algorithm has been 
proposed for practical use yet.  
 
5.6. Food Allergy  
In a recent study a total of 77 food allergy apps were analyzed [76]. While some of them exclusively 
provide information (24.6%), the majority (67.5%) includes various tools, such as food scanners 
(27.5%), food diaries (23.5%), and symptom trackers (21.5%). Only six Apps contained both food 
allergy education material and tools. Additional features included allergy-friendly restaurant locators 
and educational games for children. However, no App enabled the creation of a personalized Food 
Allergy Action Plan generated by a specialized HCP. The authors concluded, that most of the food 
allergy Apps examined offered an incomplete spectrum of information for patients [76]. In contrast 
to other fields of allergy, no studies have been performed in order to evaluate the benefit of food 
allergy related mHealth technologies. 
 
Mobile health in food allergy may play a role for different stakeholders including patients and 
patient organizations, doctors and allergy organizations but also the food industry [77—83, 11, 12]. 
Within food allergy different levels of medical management can be approached by mHealth tools. At 
the level of diagnosis mobile health tools can support patients for the documentation of symptoms. 
With respect to the labeling of allergenic substances in food items, EU legislation has provided a list 
of food allergens, which are required to be labelled. Barcodes are already used for food labeling and 
support patients for the identification of appropriate products. Apps dedicated to the identification 
of declared allergens in food products [e.g. ShopWell®, ipiit® and others] are widely distributed, but 
lack validation and often do not declare their source of information. Other Apps support allergy 
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patients in the selection of appropriate products, based on their specific allergen profile [e.g. 
FoodMaestro App®]. In case of an accidental contamination during food processing, effective alert 
systems for patients, are desirable. Further, tools translating food names into images or other 
languages are useful for food allergic patients when travelling to countries where their native 
language is not spoken. 
 
Other mobile health applications in food allergy support self-management for acute reactions. These 
tools are similar to those used for anaphylaxis in general and will be discussed below.  
 
Taken together, mobile health could have a significant impact on the management of food allergy. 
However, clinical validation of high quality tools is necessary before their distribution in order to 
avoid over-diagnosis and the occurrence of avoidable reactions due to inaccurate information. Close 
collaboration between the different stakeholders and further research are urgently needed.  
 
5.7 Anaphylaxis 
Currently mHealth tools are primarily used in patients with anaphylaxis for educational and 
interventional purposes [84, 13]. Potential stakeholders are patients and patient organizations as 
well as doctors and allergy organizations. Educational materials can increase the knowledge among 
the above mentioned target groups but also other individuals like teachers, nurses, preschool 
personnel and family members or other persons which may need to act during an anaphylactic 
reaction. The recognition of key symptoms can be supported by offering visual examples (photos, 
videos). The performance of acute treatment measures, especially the application of an adrenalin 
auto-injector (AAI) can be enhanced through anaphylaxis action plans delivered via mHealth 
technologies. This support may be implemented through direct audio instructions or automated 
emergency calls. Novel alert systems to identify carriers of epinephrine auto-injectors and 
emergency departments in proximity are currently in development and require a further evaluation. 
 
Automatic alerts signaling to the patient the expiration of his/her adrenalin auto-injector have 
already been successfully used [85,86]. As anaphylaxis is life threatening but rare, the development 
and implementation of mobile training tools is of high priority to facilitate repeated training and thus 
optimize the competence of patients, doctors and other persons involved. Large amount of 
materials are available [87, 88]. A recent clinical trial on the use of a smart-case for epinephrine 
autoinjectors showed improved satisfaction related to decreased anxiety among patients using the 
device [89]. Further, participants reported on improved adherence to carrying the injector and 
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better involvement in anaphylaxis management. Despite these promising results, future research 
needs to include prospective clinical trials assessing the improved clinical outcome of anaphylactic 
patients within the context of mobile health tools. 
 
5.8. Venom Allergy 
Although mHealth technologies may be very useful for prevention and management of venom 
allergy, the number of existing applications is limited. Apps could be used to graphically report the 
presence of different Hymenoptera species or non-common species in certain regions. Hikers or 
travelers may use them to make pictures of species, which will be automatically identified and 
reported. This can be used as a base for warning systems of potentially dangerous insects. 
Moreover, mHealth can serve to communicate with emergency departments or authorities in 
isolated regions or when no help is present in case of a potentially severe allergic reaction [13]. 
mHealth also might help to record and identify the culprit insect after a stinging event. Hence, all 
these possible applications could improve the identification of Hymenoptera venom-allergic patients 
and could contribute to the prevention of severe reactions. With regard to the recognition and 
management of acute reactions, please refer to the chapter on anaphylaxis (5.07). 
 
Furthermore, mobile applications should be developed to monitor the treatment course of venom 
immunotherapy (VIT), including dosage, local or systemic adverse reactions and reminders of the 
subsequent appointment to receive the next dose. Studies are needed to assess whether mHealth 
may also improve adherence and make patients co-responsible for their own treatment, as well as 
increase the awareness of the importance and suitability of venom immunotherapy. 
 
5.9. Drug Allergy  
mHealth Apps for drug allergy have been developed mainly for educational purposes to help 
distinguish adverse drug reactions between those which are pharmacologically explicable  and those 
due to immediate or delayed hypersensitivity [90].  
 
Very few apps specifically dealing with drug allergy have been developed. Therefore, there is an 
urgent need for applications providing information in the following areas: different manifestations of 
drug hypersensitivity, drug interactions/cross-reactivity, common differential diagnoses, frequent 
elicitors of different types of drug hypersensitivity and a list of brand names indicating related 
generic drugs in different countries. It should also include suggested therapeutic alternatives when a 
drug or class of drug is implicated. Quality control in the development of Apps is especially relevant 
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in the field of drug allergy as unintended use of drugs the patient is allergic to is quite common and 
reactions can be potentially life threatening. Apps aimed at the distinction between hypersensitivity 
reactions and those caused by other mechanisms are not recommended for being used by patients, 
as this requires specialized professional assessment. Also the re-evaluation of previously recorded 
but possibly yet unconfirmed drug allergies, may be assisted by digital health technology. 
 
5.10. Complementary and Alternative medicine  
Apps on Complementary and Alternative Medicine (CAM) have been developed, promising allergy 
relief with practices such as Acupressure and Hypnotherapy, but also diagnosis (e.g. detection of 
food sensitivities with a compatible heart monitor via “Bulletproof Food Detective”). EAACI has 
expressed opposition to unconventional diagnostic tests and discourages their use [91, 92]. Products 
and methods of CAM are not free of adverse-effects [93]. A competent mHealth App should be in 
accordance with evidence-based medicine, thus the use CAM Apps is not indicated.  
 
6. Research  
In addition to the transfer of information between patient and HCP, mHealth technologies entail 
new opportunities for research, especially epidemiological studies. These will profit greatly from the 
integration of real-life patient experience with increased technical savvy.  
 
Mobile health technology offers enormous possibilities for allergy research in several aspects: 
epidemiology, surveillance, health economics, public-health, clinical diagnosis, monitoring therapy.    
 
• Epidemiology: Data collection through Apps allows extremely rapid collection of data from 
populations of allergic patients; this will tremendously increase the dimensions of epidemiological 
studies in all areas of medicine, including allergology; 
• Surveillance: the use of electronic clinical diaries make the daily monitoring of symptoms of 
huge amounts of patients possible, allowing easy and cost-effective real-life studies on the use and 
efficacy of drug therapy and allergen immunotherapy; additional data on pollen and spore 
concentrations give the base for establishing individual exposure-symptom-thresholds. 
• Health Economics: Apps dedicated to monitoring patients treated in real life conditions will 
allow rapid and valid collection of data for health economic studies aimed at measuring the 
economic impact of new and old diagnostic procedures and treatments; 
• Public-Health:  Allergy Apps offer the possibility of daily monitoring the population of 
patients, whose position in a given administrative area is identifiable with geo-localization tools; this 
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possibility will facilitate the development of public health programs aimed at managing pollen 
allergy and other diseases whose symptoms are triggered by environmental factors; this will open-
up opportunities to treat pollen allergy at community level, thus improving the cost-benefit ratio of 
allergy care in the population; 
• Clinical Diagnosis: mobile Health has great potential to improving allergy diagnosis in this 
new Era of Precision Medicine; for example: the use of electronic clinical diaries allows matching the 
data of the individual patient with the trajectories of environmental triggers registered by public 
agencies, identify the patterns of triggers relevant for the patient and implementing appropriate and 
personalized prevention strategies;   
• Apps linked to diagnostic device: smart phones are becoming the conveyor of objective data 
acquired by all sorts of diagnostic devices and biosensors; Apps integrate these data with other 
information acquired or entered by the patient and allow a steady monitoring of the patient 
symptoms and parameters; research in this area will change the way of advancing diagnosis of 
allergic diseases.  
 
7. Facts and Recommendations  
The advantages and opportunities illustrated above in the management of the allergic patient is 
counterbalanced by a long list of barriers.  EAACI takes these challenges seriously while planning 
activities in this novel area of medicine:  
 
Patient-Doctor Relationship  
Facts: mHealth technologies offer valuable possibilities of communication and consultation even 
outside regular office hours. Furthermore, delocalization of the patient´s data could facilitate remote 
second consultations with allergy specialists.  
Recommendation: Direct and close contact between HCPs and patients (blended care) is 
fundamental for good patient care and should never be totally replaced by digital technology.  
 
Quality control (medical + technical)  
Facts: Patients and HCPs will be increasingly encouraged to use Allergy Apps whose quality, safety, 
efficacy, reliability and appropriateness is not verified by any public health authority or scientific 
organization. It is also often difficult to evaluate the technical appropriateness of Apps and related 
devices connected to the smartphone. 
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Recommendation: the CE certification as a medical device should always be a pre-condition for the 
certification or distribution of an Allergy App. Still, a certification does not free the physician of the 
responsibility to monitor the use and data outputs of applications. 
 
Legislation 
Facts: European (and Non-European) regulations on mobile health technology are growing in 
number, relevance and heterogeneity (see section 3.01).  
 
Recommendations: Apps certified or produced by EAACI must respect recent rules (EU - General 
Data Protection Regulation) established at European level and their future upgrade. Moreover, 
country-specific rules will have to be taken into account at local level.  
 
Licensing 
Facts: the use of mobile health and telemedicine in the management of the allergic patient allows 
delivery of remote care by doctors who may have no license or credentials to practice as a doctor in 
general or even an allergy specialist where the patient is living. 
Recommendations:  medical licensing systems need to be adapted to this new situation. 
 
Privacy and confidentiality 
Facts: privacy and protection of sensitive data is one of the most common weak points of allergy 
Apps available on the digital market.  
Recommendations: EAACI will not recommend the use of allergy Apps that are not compliant with 
the current European and local legislation on this matter.  
 
Data Overload 
Facts: Although the easy and rapid collection of large data sets is a great advantage of mHealth 
technologies, the processing and evaluation of these data represents a significant challenge for 
HCPs.  
Recommendations: App developers should pay attention to this fact and integrate solutions for 
manageable data sets including incorporation into EMR (electronic medical/health records). To 
provide continuous and safe care, further actions related to the interpretation of acquired data need 
to be planned carefully in advance. 
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Ethical prerequisites 
Facts: The rapid development of mHealth technologies enables external persons, companies and 
institutions to access the private sphere of a multitude of users. This accessibility does not only 
facilitate data collection, but also interventions. Both action require consideration of ethical aspects.  
Recommendations:  Apart from legal aspects, EAACI emphasizes that any development and 
performance of Apps requires careful ethical consideration.  
 
Reimbursement 
Facts: In most countries, the time and expertise spent by doctors and specialists in assisting their 
patients through Apps or other telemedicine tools is not paid; this limits more rapid adoption of new 
technology. Health insurance companies/systems and public administration are slowly 
acknowledging this problem but reimbursement practices are in their infancy and rather sparse and 
episodic.  
Recommendations: The use of validated mHealth tools should be reimbursed if used for improved 
care in the clinical practice of doctors.  
 
Interference with disease management plans 
Facts: improper use of Apps and other telemedicine tools may threaten the continuity of the 
relationship between the patient and his doctor, increasing the tendency to inappropriately  self-
care unguided by a proper disease self-management plan.  
Recommendations: doctors should be aware of this risk and address it directly with their patients. 
Both parties should know the Apps and devices used by the patient. mHealth should be established 
as a form of blended care within any integrated care pathway. 
 
Interoperability 
Facts: The harmonization of different data management systems is a significant challenge for IT 
developers and HCPs.  
Recommendations: The integration of mHealth data into electronic health records, e.g. at hospitals, 
outpatient clinics or within primary care is fundamentally important to ensure continuity of care. 
 
Accessibility 
Facts: A non-negligible proportion of the European population does not have access to a 
smartphone nor has sufficient health and digital literacy [94].  
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Recommendations: The experience acquired by WHO programs on mHealth in low- and middle-
income countries may be useful to face this challenge also in Europe. 
 
Accreditation and Training 
Facts: There is no accreditation system for the use by doctors of mobile health technology, nor is this 
area part of the curriculum for doctors or specialists; the level of awareness and education of 
doctors in the use of mobile Health technology is extremely low. 
Recommendations: The correct and careful use of mobile health technologies and telemedicine 
tools should become part of the curriculum in the training of health care professionals in order to 
ensure an adequate level of awareness.  
 
Research 
Facts: Mobile health technology offers enormous possibilities for research. Published studies on the 
use of mobile health in allergic diseases are still very limited. 
Recommendations: Research on the use of mHealth in allergic diseases requires urgent funding and 
expansion in every area, such as epidemiology, surveillance, health economics, public health, clinical 
diagnosis, monitoring therapy.  
 
8. Conclusions  
Allergology, as any other area of medicine, will be deeply influenced by mobile Health technology. 
Allergists and their patients have a new way of communication, through the phone camera, -sound 
recording system, -motion sensors, texting and ultimately by using diagnostic devices and diagnostic 
algorithms incorporated within the mobile phone itself. The revolution that these possibilities are 
bringing in epidemiology, care, and research has already arrived. The role of doctors, and in 
particular allergists, will be progressively altered. To contribute to this trend, the EAACI Task Force 
for mHealth and Allergy has designed a two-years long action plan (2018-2020) that will be 
implemented under EAACI leadership [e-repository]. Accordingly, EAACI recognizes the advent of the 
m-Health Era in medicine and contributes to its development proactively.  
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Table 1 Selected overview of allergy-related apps and their most important features (apps are categorized and sorted alphabetically) 
 
 App (Name) Purpose Medical Information Technical Characteristics Additional Information 
A
lle
rg
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h
in
it
is
 
Allergy-
monitor   
 Improvement of allergy 
diagnosis (matching SMS 
and pollen) 
 Enhancement of patient-
doctor communication 
 Improvement of 
adherence to therapy and 
AIT 
 Short-term prediction of 
patients’ symptoms 
 Several Symptom and 
Medication Scores (RTSS, 
AdSS, RMS, ACS, dCSMS, VAS)  
 Asthma score 
 QoL score 
 Matching SMS and pollen 
trajectories (AV) 
 
 Patient report (eye, nose, asthma symptoms, 
medication intake, side effects) 
 Customized over-the-counter and prescribed 
medication list for all countries 
 Patient-doctor communication via SMS and e-
mail 
 Patient alerts for better adherence 
Number of Downloads: 5K+ 
Languages: 11 
Costs:  
App-Free / Backend-Charged 
Website:  
http://www.tpsproduction.com/ 
 
AllyScience  Monitoring of allergic 
rhinoconjunctivitis and 
asthma symptoms 
 Pollen information 
 Community symptom 
reports 
 Monitoring of allergic rhinitis 
symptoms 
 Pollen and symptom forecasts 
 Geolocation 
 Explicit data collection for 
study purposes 
 Users enter their 3 most attended locations 
 Patient report (eye, nose, asthma symptoms) 
 Community reports from other users 
 Pollen information and forecast 
 
Number of Downloads: 1K+ 
Languages: 5 (only available in 
Switzerland) 
Costs: Free 
 
Website: https://allyscience.ch/ 
MACVIA-
ARIA  
MASK-Air 
(previously: 
Allergy Diary)                        
 Assessment of symptoms 
and medication use in 
patients with allergic 
rhinitis 
 VAS for allergic rhinitis, 
conjuntivitis, asthma and work 
productivity 
 Recording of medication use 
 WPAI-AS (Allergy-specific 
Work Productivity and Activity 
Impairment Questionnaire) 
 Results on adherence to 
treatment, medications 
 Clinical Decision Support 
System  
 EQ5-D 
Customized over-the-counter and prescribed 
medication list for all countries  
Number of Downloads: 15K+ 
Languages: 16 
Costs: Free 
Website: 
http://www.allergydiary.com/all
ergy-diary-app/ 
 
Pollen App  Allergen avoidance by the 
means of pollen 
information and forecasts 
 Symptom information 
 Documentation of allergic 
symptoms and medication use 
 Allergy risk assessment 
 Therapy recommendations 
 Calculation of hourly allergy risk based on 
pollen forecasts 
 Personal pollen information 
 Symptom diary 
Number of Downloads: 100K+ 
Languages: 6 (with PASYFO: 9) 
Costs: Free 
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 Plant encyclopedia 
 Pollen alarm (Countdown for the season, push 
notifications for selected levels and 
aeroallergens) 
Website:  
https://www.polleninfo.org/DE/
en/free-pollen-app.html 
 
A
st
h
m
a 
Asthma 
Action Hero 
Clinical Diary and Support for 
Asthma Patients 
 Daily interactive plan including 
a detailed overview of how to 
identify moderate to severe 
symptoms of an asthma attack 
 Clinical Diary of asthma 
symptoms 
 List of prescribed medication 
 
 Symptom and medication log can be shared 
with the doctor 
 Reminder system for medication intake 
Number of Downloads: 100+ 
Languages: 1 (English) 
Costs: Free 
 
Website: 
http://www.asthmaactionhero.c
om/ 
Asthma MD Assessment of symptoms and 
medication use in patients 
suffering from asthma 
 Clinical Diary of asthma 
symptoms 
 Registry of Peak Flow Meter 
Measurements 
 Correlation of asthma 
symptoms with environmental 
triggers 
 
Patient report can be shared with the doctor Number of Downloads:  10K+ 
Languages: 1 (English) 
Costs: Free 
Inspirer-
mundi 
Assess and promote:   
1) adherence to preventive 
inhalers and 
2) asthma control 
 Therapeutic plan with 
personalised  notifications; 
 verified assessment of 
treatment adherence;  
 monitoring of asthma 
symptoms and burden; 
 asthma and rhinitis control 
(CARAT - Control of Allergic 
Rhinitis and Asthma Test) 
 detection of inhaler use (6 inhalers with dose 
counter) by processing  of video images 
captured with the smartphone camera 
 Three components: Monitoring (disease 
status and inhaler adherence), gamification 
(player starts as a “warrior” and evolves to 
become an “inspirer”) and peer support 
 Graphical display of monitored data  
 Transmission of  data to physician  
 messaging system 
 privacy and security features 
 
Number of Downloads: 100+ 
Languages: 2 (Portuguese, 
Spanish) 
Costs: Free 
Website:   
https://www.facebook.com/Proj
eto-Inspirers-
218849795347948/ 
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My Air Coach Support for Asthma Patients  Sensors monitor and store 
several physiological, 
behavioural and 
environmental factors that 
will be crossed with asthma 
data. 
 Creation of tailored asthma 
plans.  
 Available only for Android  
Languages: 1 (English) 
Costs: Free 
Website: 
http://www.myaircoach.eu/ 
D
e
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l D
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e
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e
s 
My Eczema 
Tracker 
For patients with atopic 
dermatitis 
Eczema tracker based on the 
validated Patient oriented Eczema 
measure 
Total symtpom score is calculated and scores are 
graphically displayed over time 
Number of Downloads: 100+ 
Languages: 1 (English) 
Costs: Free 
Website: 
https://nationaleczema.org/wha
t-is-measured-is-managed/ 
 
PO-SCORAD Self assessment  to better 
monitor and better treat for 
patients with atopic eczema 
Eczema severity score Severity including itch can be recorded, 
developments will be shown in diagnams, patient 
can send a screenshot to the doctor, add photos 
Number of Downloads: 5K+ 
Languages: 22 
Costs: Free 
Website: 
https://www.poscorad.com/#/ 
Skin Safe For patients with allergic 
contact dermatitis: lists 
products with contact 
allergens  
Information about allergens in skin 
care products 
 Creates an individualised allergen list through 
health care provider according to patch test 
results. 
 Shows cosmetic products safe for the allergic 
patient 
 After scanning a product: report on contained 
allergens relevant for the patient 
 Information on hypoallergenic products,  
 personalized list of  favorite products 
 helps to buy products directly from retailers 
Number of Downloads: 1K+ 
Languages: 1 (English) 
Costs: Free 
Website: 
https://www.skinsafeproducts.c
om/apps 
 
Developed with the MayoClinic 
Lots of products, mainly on the 
American market 
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Urticaria app For patients with urticaria Information and monitoring of 
urticaria  
 Gives information on symptoms and dagnosis 
of urticaria, calculates the score for the 
urticaria control test, the 7-day urticaria 
activity score and the angeioedema activity 
score and creates a diary over time. 
 
 Developed by  the Global Allergy and Asthma 
patient platform, which is sponsored by 
pharmaceutical companies including Novartis, 
several similar Apps by Novartis 
 
 
Number of Downloads: 1K+ 
Languages: 2 (English, German) 
Costs: Free 
Website: 
https://play.google.com/store/a
pps/details?id=at.alysis.urticaria
&hl=de 
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Allergy 
Journal  
Nutrition and Symptoms Diary  Individual documentation of 
ingested foods and symptoms 
facilitate the interpretation of 
delayed reactions. 
 Alert for offending foods. 
 Detailed reports to be sent by e-mail and 
exported on request as PDF or Excel 
 Data storage on phone or linked dropbox 
Number of Downloads:  ? 
Languages: 1 (English) 
Costs: iOS: 0,99€; Android: 1,09€ 
Website: 
https://itunes.apple.com/de/ap
p/allergy-
journal/id455223808?mt=8  
Anaphylaxis  Smartcase for 
epinephrine 
autoinjectors that 
connects wirelessly to a 
mobile application or 
works autonomously 
 Expiration date 
monitoring 
 Find Device Near me Map 
(pharmacies and 
hospitals)  
 parental control 
 information for the 
doctor 
 medical information 
 
 Allows the user to know at any 
time the condition of his/her 
epinephrine.   
 activates action plan in the 
event of anaphylaxis, giving 
clear instructions on how to 
administer the drug and 
notifying your pre-defined 
contacts of the incident, giving 
your exact location. 
 Warns the user when too far 
away from the autoinjector 
 Training for correctdrug 
administration 
 Report about the temperature and conditions 
of the medication (adrenaline) 
 Controls transparency of Adrenaline 
 GPS localization of the patient suffering an 
anaphylactic reaction and warns the preferred 
contacts that the patient is suffering an 
anaphylactic reaction 
 Shows pharmacies and hospitals close to the 
user 
Number of Downloads: < 5K 
Languages: 2 
Countries: 27 
Costs: Free 
 
Website: 
http://www.adanmi.com/anapp
hylaxis/ 
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e-symptoms Electronical symptom diary  Personal profile 
 To observe, quantify and 
document symptoms, 
complaints and lifestyle habits 
 Advice section 
 Information material from the 
aha! Allergy Center 
Switzerland 
Symptom diary 
Informative section 
Number of Downloads: 5K+ 
Languages: 4 
Costs: free 
Website: https://www.aha.ch/  
FoodMaestro 
APP® 
Shopping advisor for patients 
with food allergy 
 Multiple profiles for different 
family members 
 Individual recommendation 
on healthy non-offending 
foods  
 Shopping recommendations 
from a doctor or dietician can 
be saved 
 Individual shopping lists 
 Barcode scanner with different nutrition 
preferences and allergy pre-settings 
 Recommendations of products which suit the 
personal profile 
Number of Downloads: 46K 
Languages: 1 (English) 
Costs: free 
 
Website: 
https://www.foodmaestro.me/h
ome.html 
ipiit® Shopping advisor for patients 
with food allergy 
 Support for buying healthy 
groceries and managing food 
allergies. 
 Information on the 
background of different 
recommendations 
 Offering alternative products 
 Barcode scanner with preference selection 
(Gluten-free, Lactose-free and non-GMO).  
 Compares products and ingredients - calories, 
fat, sodium, carbs, fiber, sugar, protein and 
iron.  
 Community ratings 
Number of Downloads: 10K+ 
Languages: 1 (English) 
Costs: free 
 
Website: https://www.ipiit.com/ 
Lifesaver This app allows the patients 
affected by anaphylaxis to 
become familiar with their 
illness and the handling of its 
auto-injector of adrenaline. It 
also incorporates tools that 
facilitate the patient's 
awareness to their 
environment on allergic 
reactions more serious. 
 It trains about the use of the 
adrenaline autoinjector 
 Alerts about the date of 
expiration of the adrenaline 
autoinjector 
Training on how to administer the drug Number of Downloads: 100+ 
Languages: 18  
Costs: Free 
 
Website: 
https://www.lifesaverapp.com/ 
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Rescufy Connecting the patient and 
caretakers to medical help 
when anaphylaxis strikes. 
 Connecting epinephrine 
injector to mobile phone 
including an alert if the user is 
too far away from the device 
 Communicates vitally 
important allergy, medical and 
insurance information to 
Emergency Responders and 
emergency contacts 
 Captures information on allergies, any 
treatment previously administered, other 
medical conditions and insurance details 
 Information on prescribed emergency 
medication 
 Sends geolocalisation to key contacts and 
emergency responders 
 automatic dialling of emergency number (911) 
when activated 
 Patient alerts for better adherence 
  
Number of Downloads: 100+ 
Languages: 2 
Costs: Free 
ShopWell® Shopping advisor for patients 
with food allergy 
 Personal profile 
 Alerts about offending foods 
and provides 
recommendations on 
new/alternative shopping 
options available in the same 
store 
 Bar code scanner to find the ingredients in 
about 400,000 foods. 
 Personalized food recommendations 
 Location awareness to find products in your 
local grocery store 
 S Health integration for personalized nutrition 
labels 
Buy recommended foods right from the app with 
our easy mobile shopping feature 
Number of Downloads: 100K+ 
Languages: 1 (English) 
Costs: free 
 
Website: 
https://www.innit.com/shopwell
/ 
  
